Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
6
self-reported 2–10 band
Founded
2016
10 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
3
Private equity · Feb 2024 · US$ 21.0M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
PROTA THERAPEUTICS PTY LTD
ABN56614991356
Legal entities
Show as table · Prota Therapeutics: 1 registry entity
| PROTA THERAPEUTICS PTY LTD | ABN 56614991356 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Prota Therapeutics is a late clinical-stage biotech company dedicated to advancing allergen oral immunotherapies for treating food allergies, particularly addressing the prevalent and potentially life-threatening issue of peanut allergy.
PRT120 is Prota’s lead candidate and the first oral immunotherapy designed specifically to induce long-lasting remission of peanut allergy. Using a novel, proprietary dosing regimen with a rapid build-up to a high-dose maintenance phase over 18 months, PRT120 induces immune changes that switch off peanut-specific IgE production, the underlying driver of peanut allergy. In a Phase 2b clinical trial, PRT120 achieved best-in-class protection and was the first therapy to demonstrate remission and sustained protection off-treatment. Prota’s plans to advance PRT120 into a Phase 3 clinical trial in the U.S.
Prota was founded to develop and commercialize novel oral immunotherapy treatments and holds an exclusive license to the proprietary food immunotherapy technology developed at the Murdoch Children’s Research Institute.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|
All codes: AU
Addresses
- Level 14/90 Collins St; Melbourne, 3000, au
Grid intelligence Members
Funding
Rounds3
Round typePrivate equity · venture round
Amount (USD)21,000,000
Stage rank6
Investors named1
Since last round1 yr 11 mo
Funding
Show as table · 3 funding rounds
| Rounds | 3 |
|---|---|
| Axis | 2016 to 2026 |
| Private equity · 16 Feb 2024 | US$ 21.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Prota Therapeutics?
One Victoria entity on the ABR: PROTA THERAPEUTICS PTY LTD (ABN 56 614 991 356), high confidence.
How many people work at Prota Therapeutics?
6 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Prota Therapeutics have offices?
One address on record, Australia only.
Has Prota Therapeutics raised funding?
Three rounds. Latest 16 February 2024: private equity, US$21,000,000, investor SPRIM Global Investments.
Which companies are listed alongside Prota Therapeutics?
Four peer profiles on record: SPRIM Global Investments and CSL.